Objective: Hepatectomy and transplantation cause liver damage through ischemic reperfusion and oxidative stress. There is no treatment available to improve liver regeneration and reduce ischemic-reperfusion injury. The present study aimed to investigate whether a selective phosphodiesterase III inhibitor, Cilostazol, improves ischemic reperfusion injury and liver regeneration following extended hepatectomy. Material and Methods: Wistar albino rats (n=40) were randomized and divided into 4 equal groups. All rats underwent 60% hepatectomy, and Cilostazol (5 mg/kg per day) was administered to the experimental group. The subjects were sacrificed on the 4th and 7th days following the resection. Blood samples were taken to evaluate liver enzymes (ALT, AST) and liver tissue samples were taken to analyze morphology. Biochemical, morphological, and histopathological parameters were compared between Groups. Results: No statistically significant differences were detected in ALT, AST values , and relative liver weights in rats treated with Cilostazol compared to the control group without Cilostazol. Although not statistically significant, a significant increase was detected in relative liver weight and a decrease in AST value in rats treated with Cilostazol. SOD activity was found to be significantly higher and GSH levels, MPO and AOPPs levels were significantly lower in Cilostazol applied Groups. It is seen in these findings that selective inhibition of PDE3 by Cilostazol improves hepatic circulation. It was also found that ischemic reperfusion injury decreased and regeneration markers such as mitosis index, even nucleus, and proliferating cell nuclear antigen ratio increased in rats treated with Cilostazol. Conclusion: The present study found that selective PDE3 inhibitor Cilostazol positively affected the histopathological parameters following extended liver resection and significantly increased hepatocellular proliferation.
{"title":"The effects of a Cilostazol, a selective phosphodiesterase III inhibitor, on liver ischemic-reperfusion injury and liver regeneration; In vitro experimental study","authors":"Erkan Aksoy, Z. Ergenç, H. Ergenç","doi":"10.36472/msd.v10i8.978","DOIUrl":"https://doi.org/10.36472/msd.v10i8.978","url":null,"abstract":"Objective: Hepatectomy and transplantation cause liver damage through ischemic reperfusion and oxidative stress. There is no treatment available to improve liver regeneration and reduce ischemic-reperfusion injury. The present study aimed to investigate whether a selective phosphodiesterase III inhibitor, Cilostazol, improves ischemic reperfusion injury and liver regeneration following extended hepatectomy.\u0000Material and Methods: Wistar albino rats (n=40) were randomized and divided into 4 equal groups. All rats underwent 60% hepatectomy, and Cilostazol (5 mg/kg per day) was administered to the experimental group. The subjects were sacrificed on the 4th and 7th days following the resection. Blood samples were taken to evaluate liver enzymes (ALT, AST) and liver tissue samples were taken to analyze morphology. Biochemical, morphological, and histopathological parameters were compared between Groups.\u0000Results: No statistically significant differences were detected in ALT, AST values , and relative liver weights in rats treated with Cilostazol compared to the control group without Cilostazol. Although not statistically significant, a significant increase was detected in relative liver weight and a decrease in AST value in rats treated with Cilostazol. SOD activity was found to be significantly higher and GSH levels, MPO and AOPPs levels were significantly lower in Cilostazol applied Groups. It is seen in these findings that selective inhibition of PDE3 by Cilostazol improves hepatic circulation. It was also found that ischemic reperfusion injury decreased and regeneration markers such as mitosis index, even nucleus, and proliferating cell nuclear antigen ratio increased in rats treated with Cilostazol.\u0000Conclusion: The present study found that selective PDE3 inhibitor Cilostazol positively affected the histopathological parameters following extended liver resection and significantly increased hepatocellular proliferation.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87938056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL. Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL. Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.
{"title":"Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia","authors":"Rasime Derya Güleç, F. Arslan","doi":"10.36472/msd.v10i8.994","DOIUrl":"https://doi.org/10.36472/msd.v10i8.994","url":null,"abstract":"Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).\u0000Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL.\u0000Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL.\u0000Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90477384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. T. Atayoğlu, S. Atar, Ayten Guner Atayoglu, E. Demirhan, A. Ozturk, İlknur Topal, Serhad Bilim, Rumeysa Atayolu
Objective: Osteoarthritis, a degenerative joint disease, often poses challenges in conventional medical treatment, leading patients to explore traditional and complementary medicine options including apitherapy. Bee venom, known for its analgesic and anti-inflammatory properties, has been considered as a potential therapy. This study investigates the short-term safety and effectiveness of applying live bee venom in knee osteoarthritis patients. Materials and Methods: Conducted at a university hospital's Apitherapy Clinic, this single-arm clinical trial enrolled individuals diagnosed with mild to moderate knee osteoarthritis (stage 2-3). A single session of live bee venom application was administered to acupuncture points ST35, EX-LE4, and ash-chi, specifically targeting the painful knee joint. Data collection involved the utilization of a Demographic Information Questionnaire and SF-12 Scale, along with a comparison of the Numerical Rating Scale (NRS), 5 Times Sit-to-Stand Test (5xSST), and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire before and after the treatment. Results: Before the treatment, the average NRS value stood at 7.14 ± 1.7, and following the intervention, it notably decreased to 3.06 ± 2.16 (p<0.05). Additionally, the mean value for the 5xSST decreased from 14.59 ± 3.36 before treatment to 11.75 ± 2.30 after treatment. The WOMAC scale also showed a significant difference between pre- and post-treatment (p<0.05), with the mean value decreasing from 41.91 ± 18.07 before treatment to 15.57 ± 15.14 after treatment. Conclusion: The findings of this study indicate a significant improvement in the NRS, 5xSST, and WOMAC scales after the administration of live bee venom for knee osteoarthritis patients.
{"title":"Short-Term Safety and Effectivess of Apipuncture in Knee Osteoarthritis: A Single-Arm Clinical Trial","authors":"A. T. Atayoğlu, S. Atar, Ayten Guner Atayoglu, E. Demirhan, A. Ozturk, İlknur Topal, Serhad Bilim, Rumeysa Atayolu","doi":"10.36472/msd.v10i8.1007","DOIUrl":"https://doi.org/10.36472/msd.v10i8.1007","url":null,"abstract":"Objective: Osteoarthritis, a degenerative joint disease, often poses challenges in conventional medical treatment, leading patients to explore traditional and complementary medicine options including apitherapy. Bee venom, known for its analgesic and anti-inflammatory properties, has been considered as a potential therapy. This study investigates the short-term safety and effectiveness of applying live bee venom in knee osteoarthritis patients.\u0000Materials and Methods: Conducted at a university hospital's Apitherapy Clinic, this single-arm clinical trial enrolled individuals diagnosed with mild to moderate knee osteoarthritis (stage 2-3). A single session of live bee venom application was administered to acupuncture points ST35, EX-LE4, and ash-chi, specifically targeting the painful knee joint. Data collection involved the utilization of a Demographic Information Questionnaire and SF-12 Scale, along with a comparison of the Numerical Rating Scale (NRS), 5 Times Sit-to-Stand Test (5xSST), and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire before and after the treatment.\u0000Results: Before the treatment, the average NRS value stood at 7.14 ± 1.7, and following the intervention, it notably decreased to 3.06 ± 2.16 (p<0.05). Additionally, the mean value for the 5xSST decreased from 14.59 ± 3.36 before treatment to 11.75 ± 2.30 after treatment. The WOMAC scale also showed a significant difference between pre- and post-treatment (p<0.05), with the mean value decreasing from 41.91 ± 18.07 before treatment to 15.57 ± 15.14 after treatment.\u0000Conclusion: The findings of this study indicate a significant improvement in the NRS, 5xSST, and WOMAC scales after the administration of live bee venom for knee osteoarthritis patients.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85714171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Pharmacotherapy for premature ejaculation has been widely used for years. The efficacy of antidepressants, especially SSRIs, has been confirmed by many randomized controlled studies. The orthosympathetic activity on the ejaculatory system is a well-studied entity. In this study, our purpose is to evaluate the efficacy of a selective α-1 blocker, doxazosin, in the treatment of premature ejaculation. Material and Methods: The study comprised 42 patients (mean age 39.11) out of a total of 44 patients with PE who were referred to Ege University Urology Outpatient Clinic from September 2000 to June 01. Among them, 27 patients were asked to use a daily dose of 4 mg of the α-blocker doxazosin for 6 weeks. The control group consisted of 15 patients who were asked to use 4 mg of placebo (starch) in the same way as doxazosin. After a therapy of 6 weeks, all the patients were interviewed to assess the efficacy of the therapy and to report any side effects. Results: There was a significant increase in the latency of ejaculation with doxazosin in 12 out of a total of 27 patients (44.40%) compared to placebo, where only 2 out of 13 patients (13.30%) showed a similar effect. The effect of doxazosin was found to be statistically significant (p<0.043). The side effect profile showed no significant difference between doxazosin and placebo. Conclusion: The result of our study indicates that doxazosin is safe and effective in patients with PE. Its activity is comparable to phenoxybenzamine and clomipramine, as reported in the literature. Additionally, its significantly lower and milder adverse effect profile appears to be an advantage.
{"title":"Doxazosin, a Selective Alpha-1 Blocker, in the Treatment of Premature Ejaculation","authors":"Musa Karabulut, G. Günaydın","doi":"10.36472/msd.v10i8.991","DOIUrl":"https://doi.org/10.36472/msd.v10i8.991","url":null,"abstract":"Objective: Pharmacotherapy for premature ejaculation has been widely used for years. The efficacy of antidepressants, especially SSRIs, has been confirmed by many randomized controlled studies. The orthosympathetic activity on the ejaculatory system is a well-studied entity. In this study, our purpose is to evaluate the efficacy of a selective α-1 blocker, doxazosin, in the treatment of premature ejaculation.\u0000Material and Methods: The study comprised 42 patients (mean age 39.11) out of a total of 44 patients with PE who were referred to Ege University Urology Outpatient Clinic from September 2000 to June 01. Among them, 27 patients were asked to use a daily dose of 4 mg of the α-blocker doxazosin for 6 weeks. The control group consisted of 15 patients who were asked to use 4 mg of placebo (starch) in the same way as doxazosin. After a therapy of 6 weeks, all the patients were interviewed to assess the efficacy of the therapy and to report any side effects.\u0000Results: There was a significant increase in the latency of ejaculation with doxazosin in 12 out of a total of 27 patients (44.40%) compared to placebo, where only 2 out of 13 patients (13.30%) showed a similar effect. The effect of doxazosin was found to be statistically significant (p<0.043). The side effect profile showed no significant difference between doxazosin and placebo.\u0000Conclusion: The result of our study indicates that doxazosin is safe and effective in patients with PE. Its activity is comparable to phenoxybenzamine and clomipramine, as reported in the literature. Additionally, its significantly lower and milder adverse effect profile appears to be an advantage.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79340368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Thalassemia major, an autosomal recessive genetic disorder, represents a significant healthcare concern worldwide. The hallmark of this condition is the deficiency in hemoglobin synthesis, resulting in chronic anemia and necessitating regular blood transfusions. This study endeavors to delve into the realm of pediatric patients afflicted by thalassemia major, with a particular focus on investigating potential vitamin and mineral deficiencies. By exploring these deficiencies, we aim to contribute to the broader understanding of the physiological implications of thalassemia major on growing individuals, shedding light on aspects that could impact their overall health and well-being. Material Methods: The current study constitutes a retrospective analysis of a meticulously curated dataset comprising 112 pediatric patients diagnosed with thalassemia major. The patients were drawn from diverse backgrounds and were subjected to rigorous assessment and evaluation. Comprehensive medical records, encompassing demographic information, clinical history, and laboratory findings, were meticulously reviewed. Results: The patients had a mean age of 8.14±12 years; among them, 59 (52.7%) were girls. The median hemoglobin and ferritin levels were 8.5 g/dL (range 6.5-10.6) and 2497 ml/ng (range 170-7417), respectively. The frequency of erythrocyte suspension (ES) transfusion in the patients was 1:2.7 weeks. The mean serum levels were 423.7 pg/mL (range 166-755) for vitamin B12, 6.6 ng/mL (range 1.55-16.4) for folic acid, 79.4 mg/dL (range 51-167) for zinc, and 111.07 mg/dL (range 67-190) for copper. Among the patients, 7 (6.25%) had a vitamin B12 deficiency, 35 (31.25%) had a folic acid deficiency, 27 (24.1%) had a zinc deficiency, and 10 (8.9%) had a copper deficiency. Conclusion: The exploration into pediatric thalassemia major unveils a landscape where folic acid and zinc deficiencies play a significant role. The detected prominence of these deficiencies prompts a call for focused interventions to address the potential health implications. Amid the intricate fabric of thalassemia major, the spotlight on folic acid and zinc deficiencies highlights an avenue for proactive healthcare strategies. By targeting these deficiencies, we hold the potential to improve the well-being and future prospects of young patients grappling with thalassemia major.
{"title":"Clinical Management and Vitamin-Mineral Deficiencies in Children with Beta-Thalassemia Major: A Study on 112 Cases","authors":"Ö. Terzi","doi":"10.36472/msd.v10i8.990","DOIUrl":"https://doi.org/10.36472/msd.v10i8.990","url":null,"abstract":"Objective: Thalassemia major, an autosomal recessive genetic disorder, represents a significant healthcare concern worldwide. The hallmark of this condition is the deficiency in hemoglobin synthesis, resulting in chronic anemia and necessitating regular blood transfusions. This study endeavors to delve into the realm of pediatric patients afflicted by thalassemia major, with a particular focus on investigating potential vitamin and mineral deficiencies. By exploring these deficiencies, we aim to contribute to the broader understanding of the physiological implications of thalassemia major on growing individuals, shedding light on aspects that could impact their overall health and well-being.\u0000Material Methods: The current study constitutes a retrospective analysis of a meticulously curated dataset comprising 112 pediatric patients diagnosed with thalassemia major. The patients were drawn from diverse backgrounds and were subjected to rigorous assessment and evaluation. Comprehensive medical records, encompassing demographic information, clinical history, and laboratory findings, were meticulously reviewed.\u0000Results: The patients had a mean age of 8.14±12 years; among them, 59 (52.7%) were girls. The median hemoglobin and ferritin levels were 8.5 g/dL (range 6.5-10.6) and 2497 ml/ng (range 170-7417), respectively. The frequency of erythrocyte suspension (ES) transfusion in the patients was 1:2.7 weeks. The mean serum levels were 423.7 pg/mL (range 166-755) for vitamin B12, 6.6 ng/mL (range 1.55-16.4) for folic acid, 79.4 mg/dL (range 51-167) for zinc, and 111.07 mg/dL (range 67-190) for copper. Among the patients, 7 (6.25%) had a vitamin B12 deficiency, 35 (31.25%) had a folic acid deficiency, 27 (24.1%) had a zinc deficiency, and 10 (8.9%) had a copper deficiency.\u0000Conclusion: The exploration into pediatric thalassemia major unveils a landscape where folic acid and zinc deficiencies play a significant role. The detected prominence of these deficiencies prompts a call for focused interventions to address the potential health implications. Amid the intricate fabric of thalassemia major, the spotlight on folic acid and zinc deficiencies highlights an avenue for proactive healthcare strategies. By targeting these deficiencies, we hold the potential to improve the well-being and future prospects of young patients grappling with thalassemia major.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83232983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: As technology continues to advance, alternative methods of cadaver education have emerged in anatomy lessons. However, cadaver dissection remains a fundamental component of medical education curricula worldwide. Material and Methods: This research was conducted among students enrolled in health sciences and other disciplines at İzmir Bakırçay University. A total of five hundred and eighty-four students took part in the study. The survey aimed to gather information on students' sociodemographic attributes and their perspectives regarding the potential donation of their and their family members' bodies for use as cadavers after their passing. Resuts: The analysis of the study's data revealed that students in both groups expressed a reluctance to donate their own bodies or those of their family members. Nonetheless, a majority of students emphasized the significance of cadaveric education, indicating that the willingness to donate cadavers could potentially rise with increased exposure to informative advertisements and comprehensive awareness campaigns. Conclusion: Despite the prevalent Islamic faith in Turkish society, survey findings indicate that religious beliefs do not significantly impede body donation. The study reveals that the primary deterrent to body donation in Turkey is the perceived lack of professionalism within the institutions accepting such donations. To enhance body donation rates in the country, a promising strategy involves launching comprehensive body donation campaigns through mass media, effectively showcasing the competence and professionalism of the parties involved in these initiatives.
{"title":"Attitudes of students who study in different departments against body donation","authors":"Asrın Nalbant, E. Turhan, Özden Bedre Duygu","doi":"10.36472/msd.v10i8.1005","DOIUrl":"https://doi.org/10.36472/msd.v10i8.1005","url":null,"abstract":"Objective: As technology continues to advance, alternative methods of cadaver education have emerged in anatomy lessons. However, cadaver dissection remains a fundamental component of medical education curricula worldwide.\u0000Material and Methods: This research was conducted among students enrolled in health sciences and other disciplines at İzmir Bakırçay University. A total of five hundred and eighty-four students took part in the study. The survey aimed to gather information on students' sociodemographic attributes and their perspectives regarding the potential donation of their and their family members' bodies for use as cadavers after their passing.\u0000Resuts: The analysis of the study's data revealed that students in both groups expressed a reluctance to donate their own bodies or those of their family members. Nonetheless, a majority of students emphasized the significance of cadaveric education, indicating that the willingness to donate cadavers could potentially rise with increased exposure to informative advertisements and comprehensive awareness campaigns.\u0000Conclusion: Despite the prevalent Islamic faith in Turkish society, survey findings indicate that religious beliefs do not significantly impede body donation. The study reveals that the primary deterrent to body donation in Turkey is the perceived lack of professionalism within the institutions accepting such donations. To enhance body donation rates in the country, a promising strategy involves launching comprehensive body donation campaigns through mass media, effectively showcasing the competence and professionalism of the parties involved in these initiatives.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87608850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ibrahim Acir, Alper Güngör, Abbas Musa Yılmaz, Abdurrahman Yusuf Çevik, Esra Derya Dinç Polat, V. Yayla
Objective: The study aimed to investigate the conversion duration from Radiologically Isolated Syndrome (RIS) to multiple sclerosis (MS) and identify factors associated with an increased risk of progression. Materials and Methods: The study involved a meticulous review of the medical records of 18 patients diagnosed with RIS, who presented without demyelinating clinic in the first applying. Data on patient demographics, laboratory findings, and clinical outcomes were collected. Those who converted from RIS to MS and their conversion duration were recorded. Patients were categorized into two groups; group 1 who progressed to clinically definite MS, and group 2 who remained asymptomatic without clinical progression. The duration of conversion from RIS to MS was also recorded. Results: The study population had a mean age of 39.8 ± 11.5 years, with 15 females and 3 males. All male patients belonged to Group 1. Although the ages between the two groups did not significantly differ, it was noteworthy that all RIS patients were female. No significant difference between the two groups was observed in the presence of oligoclonal bands or the IgG index. Additionally, the evaluation of spinal lesions did not reveal a statistically significant disparity. The median conversion duration for patients progressing from RIS to MS was 19.5 (interquartile range: 29.25) months. Conclusion: The study provides valuable insights into the conversion from RIS to MS. The study did not identify spinal lesions, oligoclonal bands, or age as prominent indicators for predicting RIS conversion to MS. Early identification of RIS patients at higher risk of progression may enable timely intervention and improve long-term outcomes.
{"title":"Conversion from Radiologically Isolated Syndrome to Multiple Sclerosis: Single Center Retrospective Study","authors":"Ibrahim Acir, Alper Güngör, Abbas Musa Yılmaz, Abdurrahman Yusuf Çevik, Esra Derya Dinç Polat, V. Yayla","doi":"10.36472/msd.v10i8.1006","DOIUrl":"https://doi.org/10.36472/msd.v10i8.1006","url":null,"abstract":"Objective: The study aimed to investigate the conversion duration from Radiologically Isolated Syndrome (RIS) to multiple sclerosis (MS) and identify factors associated with an increased risk of progression.\u0000Materials and Methods: The study involved a meticulous review of the medical records of 18 patients diagnosed with RIS, who presented without demyelinating clinic in the first applying. Data on patient demographics, laboratory findings, and clinical outcomes were collected. Those who converted from RIS to MS and their conversion duration were recorded. Patients were categorized into two groups; group 1 who progressed to clinically definite MS, and group 2 who remained asymptomatic without clinical progression. The duration of conversion from RIS to MS was also recorded.\u0000Results: The study population had a mean age of 39.8 ± 11.5 years, with 15 females and 3 males. All male patients belonged to Group 1. Although the ages between the two groups did not significantly differ, it was noteworthy that all RIS patients were female. No significant difference between the two groups was observed in the presence of oligoclonal bands or the IgG index. Additionally, the evaluation of spinal lesions did not reveal a statistically significant disparity. The median conversion duration for patients progressing from RIS to MS was 19.5 (interquartile range: 29.25) months.\u0000Conclusion: The study provides valuable insights into the conversion from RIS to MS. The study did not identify spinal lesions, oligoclonal bands, or age as prominent indicators for predicting RIS conversion to MS. Early identification of RIS patients at higher risk of progression may enable timely intervention and improve long-term outcomes.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80736808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Cancer patients have a higher risk of COVID-19 infection compared to the healthy population. Therefore, the aim of this study is to assess the parameters and inflammatory indices that influence mortality in lung cancer patients who contract COVID-19. Material and Methods: The sample of this single-center retrospective study comprised 66 patients diagnosed with lung cancer and treated for COVID-19 between April 2020 and July 2021. The neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, prognostic index, modified Glasgow prognostic score, and COVID inflammatory score were calculated for all patients. A total of twenty-seven potential prognostic variables were identified for further analysis through univariate and multivariate analyses. Results: Seven variables with statistically significant prognostic values were identified as a result. The identified variables include having received chemotherapy in the last 28 days, hospitalization in the intensive care unit, the need for mechanical ventilation, receipt of COVID-19 corticosteroid treatment, serum uric acid level, hemoglobin level, and platelet count. The seven variables with prognostic value were subjected to Cox regression analysis. The results of the multivariate logistic regression analysis indicated that low hemoglobin and low uric acid levels emerged as independent risk factors for survival in lung cancer patients infected with COVID-19. Conclusion: To the best of our knowledge, this is the first study to suggest that serum hemoglobin levels less than 10 g/dL and serum uric acid levels less than 3.5 mg/dL can serve as prognostic factors in lung cancer patients infected with COVID-19, aiding in predicting mortality.
{"title":"Serum Uric Acid and Hemoglobin Levels as Prognostic Factors for COVID-19 Disease in Lung Cancer Patients","authors":"Semra Özkan Öztürk, Zehra Kocaman, A. Inal","doi":"10.36472/msd.v10i7.1001","DOIUrl":"https://doi.org/10.36472/msd.v10i7.1001","url":null,"abstract":"Objective: Cancer patients have a higher risk of COVID-19 infection compared to the healthy population. Therefore, the aim of this study is to assess the parameters and inflammatory indices that influence mortality in lung cancer patients who contract COVID-19.\u0000Material and Methods: The sample of this single-center retrospective study comprised 66 patients diagnosed with lung cancer and treated for COVID-19 between April 2020 and July 2021. The neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, prognostic index, modified Glasgow prognostic score, and COVID inflammatory score were calculated for all patients. A total of twenty-seven potential prognostic variables were identified for further analysis through univariate and multivariate analyses.\u0000Results: Seven variables with statistically significant prognostic values were identified as a result. The identified variables include having received chemotherapy in the last 28 days, hospitalization in the intensive care unit, the need for mechanical ventilation, receipt of COVID-19 corticosteroid treatment, serum uric acid level, hemoglobin level, and platelet count. The seven variables with prognostic value were subjected to Cox regression analysis. The results of the multivariate logistic regression analysis indicated that low hemoglobin and low uric acid levels emerged as independent risk factors for survival in lung cancer patients infected with COVID-19.\u0000Conclusion: To the best of our knowledge, this is the first study to suggest that serum hemoglobin levels less than 10 g/dL and serum uric acid levels less than 3.5 mg/dL can serve as prognostic factors in lung cancer patients infected with COVID-19, aiding in predicting mortality.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83948272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Yıldız, R. Akdeniz, Kazım Çebi, M. Albayrak, O. Ilhan
Objective: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by a hyperimmune response. Although HLH is well described in the pediatric population, less is known about the appropriate management in adults. Despite the inclusion of etoposide in HLH society protocols, some clinicians refrain from using it due to its cytotoxicity and potential adverse effects. Case: We report here the case of a 43-year-old male presenting with fever and pancytopenia, who was diagnosed with HLH following further evaluation. The patient immediately started the HLH-2004 initial protocol, which consisted of dexamethasone, etoposide, cyclosporine, and IVIG. Symptoms improved after 2 weeks of treatment. Subsequent bone marrow biopsy showed normal results, and the patient achieved complete remission, leading to the termination of treatment in the 12th week of the protocol. At 8 months post-treatment, the patient remained recurrence-free with normal hematological and biochemical test results. Conclusion: This case underscores the importance of considering etoposide-containing regimens, particularly for medically fit patients.
{"title":"Successful management of adult hemophagocytic lymphohistiocytosis with an etoposide-containing regimen: Case report and literature review","authors":"A. Yıldız, R. Akdeniz, Kazım Çebi, M. Albayrak, O. Ilhan","doi":"10.36472/msd.v10i7.975","DOIUrl":"https://doi.org/10.36472/msd.v10i7.975","url":null,"abstract":"Objective: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by a hyperimmune response. Although HLH is well described in the pediatric population, less is known about the appropriate management in adults. Despite the inclusion of etoposide in HLH society protocols, some clinicians refrain from using it due to its cytotoxicity and potential adverse effects.\u0000Case: We report here the case of a 43-year-old male presenting with fever and pancytopenia, who was diagnosed with HLH following further evaluation. The patient immediately started the HLH-2004 initial protocol, which consisted of dexamethasone, etoposide, cyclosporine, and IVIG. Symptoms improved after 2 weeks of treatment. Subsequent bone marrow biopsy showed normal results, and the patient achieved complete remission, leading to the termination of treatment in the 12th week of the protocol. At 8 months post-treatment, the patient remained recurrence-free with normal hematological and biochemical test results.\u0000Conclusion: This case underscores the importance of considering etoposide-containing regimens, particularly for medically fit patients.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87787996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Inferior vena cava (IVC) anomalies are very rare vascular embryological variations, the incidence rate in the general population is 0.5%. IVC anomalies are usually asymptomatic and detected incidentally. The inferior vena cava is formed between the 6th and 8th weeks of intrauterine embryological development. IVC occurs due to the fusion of the supracardinal, postcardinal, and subcardinal veins during the embryological period. This union results from complex anastomosis of the embryological stage veins. During this time, various IVC anomalies may develop. IVC anomalies increase the risk of deep vein thrombosis in the lower extremity. Because of the increased risk of deep vein thrombosis in these patients, anti-embolism prophylaxis can be performed before the operation. Therefore, the risk of pulmonary embolism increases as well. The use of computed tomography has become more common nowadays. The detection rate of IVC anomalies has increased in examinations performed for other purposes. Case: IVC anomalies are important in terms of surgical interventions and the use of a vena cava filter. Knowing the existence of IVC anomalies can be crucial in preventing complications that may arise during surgical and radiological procedures. The objective of this study is to present three different cases with incidentally detected IVC anomalies.
{"title":"Incidentally Detected Inferior Vena Cava Anomalies: 3 Case Reports","authors":"Demet Doğan, K. Gökçe, Miran Su Dağaşan","doi":"10.36472/msd.v10i7.987","DOIUrl":"https://doi.org/10.36472/msd.v10i7.987","url":null,"abstract":"Objective: Inferior vena cava (IVC) anomalies are very rare vascular embryological variations, the incidence rate in the general population is 0.5%. IVC anomalies are usually asymptomatic and detected incidentally. The inferior vena cava is formed between the 6th and 8th weeks of intrauterine embryological development. IVC occurs due to the fusion of the supracardinal, postcardinal, and subcardinal veins during the embryological period. This union results from complex anastomosis of the embryological stage veins. During this time, various IVC anomalies may develop. IVC anomalies increase the risk of deep vein thrombosis in the lower extremity. Because of the increased risk of deep vein thrombosis in these patients, anti-embolism prophylaxis can be performed before the operation. Therefore, the risk of pulmonary embolism increases as well. The use of computed tomography has become more common nowadays. The detection rate of IVC anomalies has increased in examinations performed for other purposes. \u0000Case: IVC anomalies are important in terms of surgical interventions and the use of a vena cava filter. Knowing the existence of IVC anomalies can be crucial in preventing complications that may arise during surgical and radiological procedures. The objective of this study is to present three different cases with incidentally detected IVC anomalies.","PeriodicalId":18486,"journal":{"name":"Medical Science and Discovery","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80347022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：